胃蛋白酶原Ⅰ与糖尿病的相关性探讨

Discussion on the relationship between the level of serum pepsinogen Ⅰ and the gastrosis of diabetes

目的探讨胃蛋白酶原Ⅰ(PGⅠ)与糖尿病及糖尿病并发症患者并发胃病的临床研究价值的相关性。方法选择255例受试者:其中对照组153例,糖尿病患者(DM)89例,糖尿病肾病患者(DN)13例,采用时间分辨荧光免疫分析法(TRFIA)检测受试者血清PGⅠ含量。结果 DN组、DM组以及对照组的PGⅠ平均水平分别为(319.68±103.25)、(201.22±167.33)、(144.85±39.4)ng/mL。DM组与对照组相比,血清PGⅠ水平要明显高于对照组(P<0.05),DN组与DM组相比,PGⅠ水平更高(P<0.01)。结论血清PGⅠ含量异常能够作为糖尿病并发症患者胃部异常的辅助诊断指标。

Objective To discuss the significance of using pepsinogen I （PG I ） to examine the gastrosis of diabetes patients. Methods 255 cases of subjects were selected,including 153 healthy people（control group） ,89 diabetes patients（DM group） and 13 patients with diabetes and nephropathy（DN group）. The serum levels of PG I were detected by time-resolved fluorescence immu- noassay（TRFIA）. Results Serum PG I levels in the DM, DN and control groups were（319. 68± 103.25）, （201.22 ± 167.33）, （144.85±39.4） ng/mL,respectively. The PG I level in serum of patients with diabetes was higher than that of control group（P〈 0.05）. The PG I level of patients with diabetes and nephropathy was much higher than that of patients with diabetes（P〈0.01）. Conclusion Pepsinogen I could be a reference marker in screening stomach trouble of patients with complications of diabetes.